Form 4: Organon Director Philip Ozuah Increases Stake Through Phantom Stock Acquisition

Organon & Co. Director Philip Ozuah reported the acquisition of 23,904.382 phantom stock units on June 13, 2025, increasing his total beneficial ownership to 62,702.657 units.

Summary

• Philip Ozuah, a Director at Organon & Co. (OGN), filed a Form 4 reporting changes in his beneficial ownership.
• On June 13, 2025, Mr. Ozuah acquired 23,904.382 phantom stock units.
• Each phantom stock unit is an economic equivalent of one share of Organon common stock, with a reported price of $10.04 per unit for the acquired units.
• These phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
• Following this transaction, Mr. Ozuah's total beneficial ownership of phantom stock units increased to 62,702.657 units.
• The total holdings include phantom stock units acquired through dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025, and June 12, 2025.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock by a director, even as part of a compensation plan, generally indicates continued alignment with the company's performance and can be viewed as a positive signal of confidence. The nature of phantom stock (cash settlement) slightly tempers the direct equity alignment, but overall it's a positive sign of commitment.

Positives

• A director increasing their beneficial ownership, even through phantom stock, can signal confidence in the company's future performance.
• The acquisition is part of a structured Non-Employee Director Savings Plan, indicating a consistent compensation and retention strategy for board members.

Negatives

• The phantom stock units are payable in cash upon termination of service, meaning they do not directly convert into common stock shares, which might limit direct shareholder alignment compared to equity awards.

Future Outlook

The phantom stock units are payable in cash upon the reporting person's termination of service as a director, aligning future compensation with continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, reflecting a director's compensation structure and beneficial ownership changes. It does not provide specific insights into broader pharmaceutical or healthcare industry trends.

Stakeholder Impact

• Shareholders: The increase in a director's beneficial ownership, even through phantom stock, can be perceived positively as it aligns the director's interests with the company's long-term performance, potentially signaling confidence.

Key Dates

Keywords

Organon & Co., OGN, Philip Ozuah, SEC Form 4, Insider Trading, Director Compensation, Phantom Stock, Beneficial Ownership, SEC Filing, Pharmaceuticals, Healthcare